In an exploratory analysis, we tested whether amyloid-positive ApoE4 non-carriers showed a stronger tau hub ratio, since previous work has suggested that ApoE4-carriage is associated with a more limbic-predominant pattern of tau pathology in AD patients16, whereas amyloid-positive ApoE4 non-carriers show a more neocortical tau pathology pattern42. This evidence concerns the gene MAPT and Alzheimer disease.